GEBP Antibody

Introduction to GBP1 Antibody

GBP1 (Guanylate-Binding Protein 1) antibodies are specialized reagents targeting the GBP1 protein, a member of the dynamin superfamily of GTPases. These antibodies are critical tools for studying GBP1's roles in innate immunity, pathogen defense, and cancer biology . GBP1 is induced by interferons (IFN-γ and IFN-α/β) and exhibits GTPase activity, enabling it to disrupt microbial membranes, activate inflammasomes, and regulate autophagy .

Molecular Properties

GBP1 antibodies recognize epitopes within these functional domains, enabling applications such as Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) .

Immune Response and Pathogen Defense

• Inflammasome Activation: GBP1 forms protein coats around Gram-negative bacteria, exposing lipid A for CASP4/CASP11 inflammasome activation .

• Antiviral Activity: Inhibits replication of influenza, encephalomyocarditis virus, and vesicular stomatitis virus .

• Antibacterial and Antiprotozoal Effects: Limits Salmonella enterica, Chlamydia trachomatis, and Toxoplasma gondii infections via bacteriolytic peptide generation .

Cancer Biology

• Antiangiogenic Role: Suppresses colorectal carcinoma (CRC) growth by inhibiting tumor angiogenesis and directly targeting tumor cells .

• Prognostic Marker: High GBP1 expression correlates with improved CRC outcomes and Th1 immune infiltration .

Validation and Quality Control

GBP1 antibody specificity is confirmed via:

1. Knockout (KO) Cell Lines: Validated in studies showing loss of signal in GBP1-KO models .

2. Orthogonal Assays: Consistent results across WB, IF, and functional assays (e.g., pathogen neutralization) .

3. Third-Party Testing: Initiatives like YCharOS and Antibody Society databases highlight the superiority of recombinant antibodies in reproducibility .

Market and Research Trends

• Global Antibody Market: Projected to grow at 9.2% CAGR (2023–2028), driven by demand for precision tools like GBP1 antibodies .

• Therapeutic Potential: Emerging interest in GBP1’s role in immunotherapy and inflammasome-targeted therapies .

Challenges and Future Directions

• Standardization: Inconsistent validation protocols remain a hurdle; third-party testing is advocated .

• Functional Studies: Further mechanistic insights into GBP1’s GTPase-dependent vs. independent functions are needed .